313 related articles for article (PubMed ID: 22475206)
1. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
2. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
3. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP
Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
5. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
7. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis.
Meijer E; Boertien WE; Nauta FL; Bakker SJ; van Oeveren W; Rook M; van der Jagt EJ; van Goor H; Peters DJ; Navis G; de Jong PE; Gansevoort RT
Am J Kidney Dis; 2010 Nov; 56(5):883-95. PubMed ID: 20888104
[TBL] [Abstract][Full Text] [Related]
8. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
9. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease.
Messchendorp AL; Spithoven EM; Casteleijn NF; Dam WA; van den Born J; Tonnis WF; Gaillard CAJM; Meijer E;
BMC Nephrol; 2018 Dec; 19(1):368. PubMed ID: 30567514
[TBL] [Abstract][Full Text] [Related]
10. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
[TBL] [Abstract][Full Text] [Related]
12. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP
Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454
[TBL] [Abstract][Full Text] [Related]
13. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
Chrispijn M; Nevens F; Gevers TJ; Vanslembrouck R; van Oijen MG; Coudyzer W; Hoffmann AL; Dekker HM; de Man RA; van Keimpema L; Drenth JP
Aliment Pharmacol Ther; 2012 Jan; 35(2):266-74. PubMed ID: 22111942
[TBL] [Abstract][Full Text] [Related]
14. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
Meijer E; Visser FW; van Aerts RMM; Blijdorp CJ; Casteleijn NF; D'Agnolo HMA; Dekker SEI; Drenth JPH; de Fijter JW; van Gastel MDA; Gevers TJ; Lantinga MA; Losekoot M; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Wetzels JF; Zietse R; Gansevoort RT;
JAMA; 2018 Nov; 320(19):2010-2019. PubMed ID: 30422235
[TBL] [Abstract][Full Text] [Related]
15. Lanreotide Reduces Liver Volume, But Might Not Improve Muscle Wasting or Weight Loss, in Patients With Symptomatic Polycystic Liver Disease.
Temmerman F; Ho TA; Vanslembrouck R; Coudyzer W; Billen J; Dobbels F; van Pelt J; Bammens B; Pirson Y; Nevens F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2353-9.e1. PubMed ID: 26073493
[TBL] [Abstract][Full Text] [Related]
16. NGAL, L-FABP, and KIM-1 in comparison to established markers of renal dysfunction.
Holzscheiter L; Beck C; Rutz S; Manuilova E; Domke I; Guder WG; Hofmann W
Clin Chem Lab Med; 2014 Apr; 52(4):537-46. PubMed ID: 24243749
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
Lantinga MA; D'Agnolo HM; Casteleijn NF; de Fijter JW; Meijer E; Messchendorp AL; Peters DJ; Salih M; Spithoven EM; Soonawala D; Visser FW; Wetzels JF; Zietse R; Drenth JP; Gansevoort RT;
Drug Saf; 2017 Feb; 40(2):153-167. PubMed ID: 27995519
[TBL] [Abstract][Full Text] [Related]
18. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease.
Parikh CR; Dahl NK; Chapman AB; Bost JE; Edelstein CL; Comer DM; Zeltner R; Tian X; Grantham JJ; Somlo S
Kidney Int; 2012 Apr; 81(8):784-90. PubMed ID: 22258321
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogues for treatment of polycystic liver disease.
Gevers TJ; Drenth JP
Curr Opin Gastroenterol; 2011 May; 27(3):294-300. PubMed ID: 21191289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
